Status:
TERMINATED
Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Sleep
Alzheimer Disease
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
This study aimed to pilot test a non-pharmacological (behavioral) treatment program targeting improved cognition through improving 24-h sleep-wake cycle in people with mild cognitive impairment (MCI) ...
Eligibility Criteria
Inclusion
- ≥65 years old
- Memory complaints verified by an informant
- Clinical diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's Disease
- General cognitive performance sufficiently persevered such that a diagnosis of Alzheimer's disease cannot be made by the site physician
- No evidence (CT or MRI scans within 12 months prior to screening) of infection, infarction, or other focal lesions and no clinical symptoms suggestive of intervening neurological disease
- Adequate visual and auditory acuity to allow neuropsychological testing
- Meets International Classification of Sleep Disorders-2nd edition (ICSD-2) criteria for insomnia or circadian rhythm disorders, or shows actigraphy evidence of sleep disturbances and excessive napping
Exclusion
- Any major neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, multiple sclerosis, seizure disorder, Huntington's disease, brain tumor or history of significant head trauma
- Any comorbid psychiatric conditions or severe personality disorder within the past 2 years (by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition), such as major depression, bipolar disorder, schizophrenia and other psychotic features
- Any uncontrolled medical conditions or systemic illness that might lead to difficulty complying with the study protocol
- History of alcohol or substance abuse within the past 2 years
- Any inadequately treated primary or secondary sleep disorder (due to medical conditions) that might confound the association
Key Trial Info
Start Date :
August 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2024
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03256539
Start Date
August 12 2021
End Date
January 31 2024
Last Update
November 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF
San Francisco, California, United States, 94121